[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2017010654A - Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. - Google Patents

Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.

Info

Publication number
MX2017010654A
MX2017010654A MX2017010654A MX2017010654A MX2017010654A MX 2017010654 A MX2017010654 A MX 2017010654A MX 2017010654 A MX2017010654 A MX 2017010654A MX 2017010654 A MX2017010654 A MX 2017010654A MX 2017010654 A MX2017010654 A MX 2017010654A
Authority
MX
Mexico
Prior art keywords
depressive
oxabicycloheptenes
oxabicycloheptanes
treatment
stress disorders
Prior art date
Application number
MX2017010654A
Other languages
English (en)
Inventor
S Kovach John
Lecca Salvatore
Mameli Manuel
Original Assignee
Lixte Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lixte Biotechnology Inc filed Critical Lixte Biotechnology Inc
Publication of MX2017010654A publication Critical patent/MX2017010654A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/32—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un método para el tratamiento de trastorno depresivo o de estrés en un sujeto afectado con el mismo, que comprenden administrar al sujeto una cantidad eficaz de un compuesto que tiene la estructura: (I) (ver Fórmula).
MX2017010654A 2015-02-19 2016-02-19 Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. MX2017010654A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118246P 2015-02-19 2015-02-19
US201662279265P 2016-01-15 2016-01-15
PCT/US2016/018679 WO2016134257A1 (en) 2015-02-19 2016-02-19 Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders

Publications (1)

Publication Number Publication Date
MX2017010654A true MX2017010654A (es) 2019-01-30

Family

ID=56689326

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010654A MX2017010654A (es) 2015-02-19 2016-02-19 Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.

Country Status (6)

Country Link
US (2) US9833450B2 (es)
EP (1) EP3258930B1 (es)
AU (1) AU2016219853B2 (es)
CA (1) CA2977256C (es)
MX (1) MX2017010654A (es)
WO (1) WO2016134257A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005084A1 (en) 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
MX2015014249A (es) 2013-04-09 2016-06-02 Lixte Biotechnology Inc Formulaciones de oxabicicloheptanos y oxabicicloheptenos.
US10071094B2 (en) 2014-07-24 2018-09-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
CA2977256C (en) 2015-02-19 2023-08-08 John S. Kovach Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
DK3294287T3 (da) 2015-05-15 2020-06-08 Lixte Biotechnology Inc Oxabicycloheptan-prodrugs

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361436A (en) * 1977-09-16 1982-11-30 Gaf Corporation Composition for plant growth regulation
US4614825A (en) * 1982-05-17 1986-09-30 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane and 7-oxabicycloheptene compounds
JPH0723367B2 (ja) * 1986-02-27 1995-03-15 サントリー株式会社 オキサビシクロヘプタン誘導体
US4931460A (en) * 1987-09-17 1990-06-05 E. R. Squibb & Sons, Inc. Post-ischemic myocardial dysfunction using thromboxane A2 antagonists
US4900723A (en) * 1988-04-29 1990-02-13 E. R. Squibb & Sons, Inc. Method of preventing or reducing venous thrombosis using a thromboxane A2 receptor antagonist in conjunction with heparin and combination
US6440726B1 (en) * 1998-12-24 2002-08-27 Florence Medical, Ltd. Expression vectors comprising multiple shear stress responsive elements (SSRE) and methods of use for treating disorders related to vasculogenesis and/or angiogenesis in a shear stress environment
IL160305A0 (en) * 2001-08-10 2004-07-25 Univ Rockefeller Compositions and methods for modulation of darpp-32 phosphorylation
US20050049334A1 (en) * 2003-09-03 2005-03-03 Slawomir Rubinsztain Solvent-modified resin system containing filler that has high Tg, transparency and good reliability in wafer level underfill applications
US20050170188A1 (en) * 2003-09-03 2005-08-04 General Electric Company Resin compositions and methods of use thereof
US20060147719A1 (en) * 2002-11-22 2006-07-06 Slawomir Rubinsztajn Curable composition, underfill, and method
US7022410B2 (en) * 2003-12-16 2006-04-04 General Electric Company Combinations of resin compositions and methods of use thereof
US20050266263A1 (en) * 2002-11-22 2005-12-01 General Electric Company Refractory solid, adhesive composition, and device, and associated method
WO2007092414A2 (en) 2006-02-06 2007-08-16 Lixte Biotechnology Holdings, Inc. Use of phosphatases to treat tumors overexpressing n-cor
CN101662939B (zh) 2007-02-06 2015-11-25 利克斯特生物技术公司 氧杂双环庚烷和氧杂双环庚烯，它们的制备及用途
US20080249130A1 (en) * 2007-02-09 2008-10-09 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
US20090035292A1 (en) * 2007-08-03 2009-02-05 Kovach John S Use of phosphatases to treat neuroblastomas and medulloblastomas
CA2700857C (en) * 2007-10-01 2016-08-02 John S. Kovach Hdac inhibitors
EP2318005B1 (en) 2008-08-01 2017-11-01 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010147612A1 (en) * 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
WO2010014141A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
US8227473B2 (en) * 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US8101600B2 (en) * 2008-12-23 2012-01-24 Brookhaven Science Associates, Llc Method of treating depression
US20120135522A1 (en) * 2009-06-18 2012-05-31 Kovach John S Methods of modulating cell regulation by inhibiting p53
US9040129B2 (en) * 2010-04-26 2015-05-26 Fujifilm Corporation Protective film of polarizer, polarizer and method for producing it, and liquid crystal display device
US20130197044A1 (en) * 2010-07-14 2013-08-01 Leo Pavliv Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists
CA2836940A1 (en) * 2011-05-24 2012-11-29 Lixte Biotechnology, Inc. Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
TWI553409B (zh) * 2011-08-31 2016-10-11 Asahi Kasei E Materials Corp Hardened
EP2870161B1 (en) 2012-06-29 2018-08-08 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
WO2014005084A1 (en) 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
WO2014137741A1 (en) 2013-03-05 2014-09-12 Lixte Biotechnology, Inc. Hdac inhibitors for treating traumatic brain injury
US10568328B2 (en) * 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
EP2968279A4 (en) 2013-03-15 2016-09-28 Lixte Biotechnology Inc SANGUINARIN ANALOG PPC2 HEMMER FOR CANCER TREATMENT
MX2015014249A (es) 2013-04-09 2016-06-02 Lixte Biotechnology Inc Formulaciones de oxabicicloheptanos y oxabicicloheptenos.
WO2015073802A1 (en) 2013-11-15 2015-05-21 Lixte Biotechnology, Inc. Protein phosphatase inhibitors that cross the blood brain barrier
EP3142655B1 (en) * 2014-05-16 2020-12-02 Cumberland Pharmaceuticals Inc. Compositions and methods of treating cardiac fibrosis with ifetroban
EP3157336A4 (en) 2014-06-20 2018-01-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
US10071094B2 (en) 2014-07-24 2018-09-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
WO2016040877A1 (en) 2014-09-12 2016-03-17 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor
US9994584B2 (en) 2014-10-15 2018-06-12 Lixte Biotechnology, Inc. Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid
CA2977256C (en) 2015-02-19 2023-08-08 John S. Kovach Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
DK3294287T3 (da) 2015-05-15 2020-06-08 Lixte Biotechnology Inc Oxabicycloheptan-prodrugs

Also Published As

Publication number Publication date
AU2016219853A1 (en) 2017-09-14
US9833450B2 (en) 2017-12-05
WO2016134257A8 (en) 2017-09-14
US20160303115A1 (en) 2016-10-20
US10413541B2 (en) 2019-09-17
EP3258930A4 (en) 2018-10-17
EP3258930A1 (en) 2017-12-27
US20180256565A1 (en) 2018-09-13
CA2977256C (en) 2023-08-08
WO2016134257A1 (en) 2016-08-25
CA2977256A1 (en) 2016-08-25
EP3258930B1 (en) 2020-12-09
AU2016219853B2 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
MX2018004947A (es) Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
PH12015502075B1 (en) Treatment of cataplexy
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
MX2019002190A (es) Uso de pridopidina para tratar distonías.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2019003069A (es) Uso de pridopidina para tratar el sindrome de rett.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2016010085A (es) Metodos para tratar lesion del cerebro leve.
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
TW201613610A (en) Use of ginsenoside M1 for treating lupus nephritis
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2016002308A (es) Tratamiento del mieloma multiple.
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
MX2016002307A (es) Tratamiento para el cancer.
HK1252359A1 (zh) 用於治療疼痛的曲唑酮和加巴噴丁的組合
MY194135A (en) Treatment and diagnosis of inflammatory disorders
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.
MX367952B (es) Método para tratar y curar leishmaniosis usando fexinidazol.
MX2018003040A (es) Metodos para el tratamiento de formas recurrentes de esclerosis multiple.
UA103888U (uk) Розчин фенолу для ін'єкцій для лікування хронічного больового синдрому